Peritoneal surface malignancy spread − reoperations after cytoreductive surgery + HIPEC
Authors:
F. Antoš; P. Bartoška; R. Vobořil
Authors‘ workplace:
Subkatedra koloproktologie, Institut postgraduálního vzdělávání ve zdravotnictví Praha
; Chirurgická klinika 1. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Bulovka, Praha
Published in:
Rozhl. Chir., 2021, roč. 100, č. 10, s. 469-474.
Category:
Review
doi:
https://doi.org/10.33699/PIS.2021.100.10.469–474
Overview
Introduction: Peritoneal malignancies (PM) are observed in about 10−30% of patients suffering from gastrointestinal malignant diseases, both in connection with the primary surgical management or as metachronous metastases due to cancer recurrence.
Methods: In the 1980s a new method of cytoreductive surgery (CRS) + HIPEC (hyperthermic intraperitoneal chemotherapy) was introduced. Today, we consider this method to be the gold standard for treatment of pseudomyxoma peritonei and peritoneal mesothelioma. The method increases overall survival (OS) of patients diagnosed with colorectal cancer, primary peritoneal and ovarian cancers. However, the disease recurs after this demanding treatment in the certain group of patients, approximately in 25−44% of patients treated for pseudomyxoma peritonei, and in 40% and up to 82% of those treated for mesothelioma and colorectal cancer, respectively. Based on literary data (PubMed-Medline, last 5 years) and our own experience we present the basic factors associated with tumor recurrence, possibility of treatment using repeated CRS + HIPEC, data regarding second-look operations, and as applicable, prophylactic HIPEC.
Conclusion: The method CRS + HIPEC provides an effective treatment of peritoneal carcinomatosis even in cases of recurrence. The second-look operations and prophylactic HIPEC may favorably affect the prognosis after primary R0 resections.
Keywords:
peritoneal carcinomatosis − cytoreductive surgery – HIPEC − recurrence after CRS − second-look operations
Sources
1. Antoš F, Vítek P, Kopic J, et al. Cytoreduktivní chirurgie a hypertermická peroperativní chemoterapie v léčbě malignit peritoneálních povrchů. Onkologická revue. 2018;2018(2):62−67.
2. Huang Y, Alzahrani NA, Chua TC, et al. Repeat cytoreductive surgery with or without perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. Am J Surg. 2017 Jun;213(6):1024−1030. doi: 10.1016/j. amjsurg.2016.09.046.
3. Votanopoulos KI, Ihemelandu C, Shen P, et al. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012 Sep;215(3):412−417. doi: 10.1016/j.jamcollsurg.2012.04.023.
4. Klaver CE, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017 Mar;19(3):224−236. doi: 10.1111/codi.13593.
5. Rana AA, Rana A, Hewett P. Multiple small bowel perforations secondary to tumor lysis − a complication of pseudomyxoma peritonei in a patient undergoing intraperitoneal chemotherapy. J Gastrointest Cancer 2020 Mar;51(1):289−291. doi: 10.1007/s12029-019-00216-x.
6. Lee TC, Wima K, Morris MC, et al. Incidence and long-term outcomes of patients requiring early reoperation after HIPEC. J Surg Res. 2019 Dec; 244:395−401. doi: 10.1016/j.jss.2019.05.046.
7. Jost E, Mack LA, Sideris L, et al. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study. Can J Surg. 2020 Feb 21;63(1):E71− E79. doi: 10.1503/cjs.002519.
8. Blaj S, Nedelcut S, Mayr M, et al. Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome. Langenbecks Arch Surg. 2019 Aug;404(5):541−546. doi: 10.1007/ s00423-019-01808-8.
9. Jacoby H, Berger Y, Barda L, et al. Implications of stoma formation as part of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg. 2018 Jul;42(7):2036−2042. doi: 10.1007/s00268-017-4450-4.
10. Klos D, Riško J, Stašek M, et al. Současné postavení cytoredukční chirurgie (CRS) a intraperitoneální hypertermické chemoterapie (HIPEC) v multimodální léčbě nádorů peritoneálního povrchu. Časopis lékařů českých 2018;157(8):419−428.
11. Bartoška P, Antoš F, Vítek P, et al. Pseudomyxom peritonea (PMP) a jeho léčba – dvacetileté zkušenosti jednoho pracoviště. Rozhledy v chirurgii 2020;99(4):159−166.
12. Robella M, Vaira M, Cinquegrana A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes. Minerva Chir. 2019 Jun;74(3):195−202. doi: 10.23736/S0026-4733.18.07649-6.
13. Manzanedo I, Pereira F, Pérez-Viejo E, et al. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecol. 2017 Apr;69(2):119−127. doi: 10.23736/S0026- 4784.16.03959-9.
14. Chua TC, Al-Zahrani A, Saxena A, et al. Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg. 2010 Oct;211(4):526−535. doi: 10.1016/j.jamcollsurg.2010.06.011.
15. Golse N, Bakrin N, Passot G, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012 Aug 1;106(2):197−203. doi: 10.1002/jso.23062.
16. Tan GHC, Chia CS, Tan SH, et al. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Clin Oncol. 2018 Oct;23(5):989−998. doi: 10.1007/ s10147-018-1301-8.
17. Chua TC, Quinn LE, Zhao J, et al. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol. 2013 Aug;108(2):81−88. doi: 10.1002/ jso.23356.
18. Sardi A, Jimenez WA, Nieroda C, et al. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Eur J Surg Oncol. 2013 Nov;39(11):1207−1213. doi: 10.1016/j. ejso.2013.08.017.
19. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009 Feb 10;27(5):681−685. doi: 10.1200/ JCO.2008.19.7160.
20. Dhir M, Ramalingam L, Shuai Y, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in adolescent and young adults with peritoneal metastases. Ann Surg Oncol. 2017 Apr;24(4):875−883. doi: 10.1245/s10434- 016-5689-y.
21. Serrano Del Moral Á, Pérez Viejo E, Manzanedo Romero I, et al. Systematic second-look surgery plus HIPEC in patients without evidence of recurrence, at high risk of carcinomatosis after colorectal cancer resection. Cir Esp. 2018 Feb;96(2):96−101. English, Spanish. doi: 10.1016/j.ciresp.2017.11.006.
22. Cortes-Guiral D, Elias D, Cascales-Campos PA, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives? World J Gastroenterol. 2017 Jan 21;23(3):377−381. doi: 10.3748/wjg. v23. i3.377.
23. Kyang LS, Valle SJ, Alzahrani NA, et al. Prevention of peritoneal recurrence in high-risk colorectal cancer and evidence of T4 status as a potential risk factor. ANZ J Surg. 2018 Oct;88(10):975−981. doi: 10.1111/ans.14428.
24. Elias D, Honoré C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011 Aug;254(2):289−293. doi: 10.1097/ SLA.0b013e31822638f6.
25. Sammartino P, Sibio S, Biacchi D, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis. 2014 Sep;29(9):1081−1089. doi: 10.1007/s00384-014-1929-4.
26. Arjona-Sanchez A, Esquivel J, Glehen O, et al. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc. 2019 Mar;33(3):854−860. doi: 10.1007/s00464- 018-6352-4.
27. Quenet F, Elias D, Roca L, et al. Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (Prodige 7): multicentric randomised open label phase 3 trial. Lancet 2021 Feb,12:256–266. doi: 1016/s1470- 2045(20)30599-4.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2021 Issue 10
Most read in this issue
- Sacral neuromodulation for faecal incontinence – 10 years experience and long-term outcomes of a specialized centre
- Bronchogenic cyst of gastric cardia – case report and literature review
- Delirious conditions in surgical ICU – case report
- Peritoneal surface malignancy spread − reoperations after cytoreductive surgery + HIPEC